Introduction {#section1-2192568219829024}
============

Intervertebral disc (IVD) degeneration is a complex and multifactorial process, influenced by genetic, nutritional, and mechanical factors.^[@bibr1-2192568219829024]^ As the degeneration cascade progresses, production of pro-inflammatory molecules such as tumor necrosis factor--α and interleukins increases. Furthermore, endplate calcification impairs nutrient flow and exacerbates the hypoxic acidic environment. Together, nutrient deprivation and inflammatory environment accelerate the cell death within nucleus pulposus.^[@bibr2-2192568219829024][@bibr3-2192568219829024][@bibr4-2192568219829024]-[@bibr5-2192568219829024]^ Consequently, levels of proteoglycans and other extracellular matrix proteins decrease leading to disc desiccation and progressive instability.^[@bibr6-2192568219829024]^ IVD degeneration is considered as one of the major underlying causes of low back pain.^[@bibr7-2192568219829024],[@bibr8-2192568219829024]^ In addition, degeneration of IVD contributes to other disc pathologies such as disc herniation, spondylolisthesis, spinal canal stenosis, or facet joint syndrome.^[@bibr9-2192568219829024],[@bibr10-2192568219829024]^

Spine fusions are one of the most common surgical approaches for discogenic back pain with the clinical success rate ranging from 50% to 70%.^[@bibr11-2192568219829024],[@bibr12-2192568219829024]^ Although existing surgical treatments provide better pain relief than the nonsurgical interventions^[@bibr13-2192568219829024],[@bibr14-2192568219829024]^ they do not address the biology of disc degeneration namely high pro-inflammatory cytokine levels or the inherent loss of nucleus pulposus cells. In addition, studies have shown surgery may lead to increased biomechanical stress and onset of degenerative cascade of adjacent segments.^[@bibr15-2192568219829024],[@bibr16-2192568219829024]^

Among the biological disc repair therapies, cell therapy has gained interest as it offers a disc regenerative potential, while being minimally invasive. A cell therapy approach aims to address disc inflammation by inhibiting aberrant cytokine production; disc rehydration and height restoration by initiating matrix anabolism, repopulating and stimulating the native cells. Various cell types have been used for IVD regeneration including disc cells, notochordal cells or stem cells.^[@bibr17-2192568219829024]^ Mesenchymal stem cells (MSCs) have immunomodulatory functions and ability to differentiate into cartilage, therefore, are considered as a potentially ideal cell source for IVD regeneration.^[@bibr18-2192568219829024]^ Previous studies have shown that MSCs isolated from bone marrow and adipose tissue can differentiate into a nucleus pulposus--like phenotype.^[@bibr18-2192568219829024][@bibr19-2192568219829024]-[@bibr20-2192568219829024]^ Co-culture experiments of MSCs with nucleus pulposus cells have shown nucleus pulposus cells proliferation and MSCs differentiation into chondrogenic cells.^[@bibr21-2192568219829024],[@bibr22-2192568219829024]^ Preclinical studies with cell therapy have demonstrated promising results in animal models.^[@bibr23-2192568219829024][@bibr24-2192568219829024][@bibr25-2192568219829024]-[@bibr26-2192568219829024]^ Transplanted MSCs have been shown to restore normal disc environment by inducing production of extracellular matrix proteins, including aggrecan and other proteoglycans, and type I and II collagen.^[@bibr18-2192568219829024],[@bibr25-2192568219829024],[@bibr27-2192568219829024]^ Some studies have also reported preservation of disc height and water content through MSCs application.^[@bibr25-2192568219829024],[@bibr26-2192568219829024],[@bibr28-2192568219829024]^ Another pilot trial in humans with MSCs of autologous origin has indicated feasibility, safety, and improvement in clinical outcomes, including improved water content.^[@bibr29-2192568219829024]^ Contrarily, Haufe amd Mork^[@bibr30-2192568219829024]^ showed that regenerative effect of intradiscal hematopoietic stem cell injection does not correlate with reduced pain, and thus does not offer clinically improved outcomes. Additionally, osteophyte formation by cell leakage was reported with MSC implantation.^[@bibr31-2192568219829024]^

Although cell therapy promises a greater potential for intervertebral disc regeneration, strong clinical evidence is lacking. Furthermore, questions concerning safety, long-term complications, efficacy in heterogeneous patient population, and cost-effectiveness of the procedure have not been addressed. The aim of this study was to systematically review, critically appraise, and synthesize evidence on use of cell therapy for intervertebral disc repair.

Materials and Methods {#section2-2192568219829024}
=====================

The methods for this systematic review followed accepted standards for systematic review/comparative effectiveness reviews for rigor, quality, and transparency including those described by the Agency for Healthcare Research and Quality (AHRQ), IOM Standards for Systematic Reviews, and the PCORI Methods Guide.^[@bibr32-2192568219829024][@bibr33-2192568219829024]-[@bibr34-2192568219829024]^

Electronic Literature Search {#section3-2192568219829024}
----------------------------

A systematic search of PubMed/MEDLINE was conducted for literature published through October 31 and through April 13, 2018 for EMBASE and [ClinicalTrials.gov](http://ClinicalTrials.gov) databases. Only studies in humans with abstracts written in English were considered for inclusion, with no other limits placed on the search. A priori inclusion and exclusion criteria are detailed in Appendix A (available online). Briefly, we sought to identify comparative studies of stem cell use versus conservative care, other disc-preserving injection treatments or surgical intervention in persons with cervical or lumbar degenerative disc disease or disc prolapse. In the absence of comparative studies, case series with ≥10 patients were considered. The search strategy included use of controlled vocabulary (MeSH terms) and key words (Appendix A). Bibliographies of included studies and relevant systematic reviews were reviewed to identify pertinent studies. Citations were dual reviewed for inclusion at both title/abstract and full text stages. ClincalTrials.gov was searched to identify studies that may have new publications.

Data Extraction {#section4-2192568219829024}
---------------

In addition to results, data abstraction included patient characteristics, demographics, lifestyle choices (eg, smoking), comorbidities (eg, obesity), cointerventions (eg, pharmaceutical, physical therapy, etc) intervention and comparator details (eg, spinal levels treated, use of anesthetic, cell preparation and concentration, delivery, etc).

Individual Study Quality {#section5-2192568219829024}
------------------------

Each included study was independently assessed for risk of bias and methodological quality by 2 reviewers (ACS, AF) using preset criteria based on criteria and methods delineated in the *Cochrane Handbook for Systematic Reviews of Interventions*, *The Journal of Bone and Joint Surgery*,^[@bibr35-2192568219829024]^ and the AHRQ with adaptations focusing on criteria associated with methodological quality.^[@bibr32-2192568219829024],[@bibr36-2192568219829024]^ Economic studies were evaluated according to The Quality of Health Economic Studies (QHES) instrument developed by Ofman et al.^[@bibr37-2192568219829024]^ Where feasible, the focus was on studies with the least potential for bias and the fewest limitations. Risk of bias assessments are detailed in Appendix B.

Data Analysis {#section6-2192568219829024}
-------------

For continuous measures from randomized controlled trials (RCTs), mean differences and corresponding confidence intervals were calculated with unpaired *t* tests used for statistical testing. Statistical testing was not performed for observational studies. Risk ratios were calculated for dichotomous outcomes from RCTs if differences between groups were or approached statistical significance using the Rothman EpiSheet.^[@bibr38-2192568219829024]^ For continuous outcomes; mean differences were calculated and 2-sample *t* tests done, if appropriate, using Graphpad Software.^[@bibr39-2192568219829024]^ Study design, heterogeneity across studies and variation in reporting precluded the pooling of data.

Overall Quality (Strength) of Body of Evidence {#section7-2192568219829024}
----------------------------------------------

For the primary outcomes of function and pain and for adverse events, the overall strength of evidence across included studies was assessed using the precepts outlined the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) working group and recommendations made by the AHRQ.^[@bibr32-2192568219829024],[@bibr40-2192568219829024][@bibr41-2192568219829024]-[@bibr42-2192568219829024]^ The overall quality of evidence was based on studies at least risk for bias. In determining the quality (strength) of a body of evidence regarding a given outcome, the overall quality may be downgraded 1 or 2 levels based on the following domains: (1) risk of bias due to study limitations, (2) consistency (heterogeneity) of results, (3) directness of evidence (eg, hard clinical outcomes), (4) precision of effect size estimates (eg, width of confidence intervals), and (5) publication or reporting bias. Publication and reporting bias are difficult to assess, particularly with fewer than 10 RCTs.^[@bibr32-2192568219829024]^ Publication bias was unknown in all studies and thus this domain was eliminated from the strength of evidence tables. The initial quality of the overall body of evidence begins as "High" for RCTs and "Low" for observational studies. The body of evidence for methodologically strong observational studies may be upgraded 1 or 2 levels if there are no downgrades in the primary domains above and one or more of the following are met: (1) large magnitude of effect, (2) Dose-response gradient, and (3) all plausible biases would decrease the magnitude of an apparent effect. The final overall quality (strength) of the body of literature expresses the confidence in the estimate of effect and the impact that further research may have on the results as follows:*High*---High confidence that the evidence reflects the true effect. Further research is very unlikely to change our confidence in the estimate of effect.*Moderate*---Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of effect and may change the estimate.*Low*---Low confidence that the evidence reflects the true effect. Further research is likely to change the confidence in the estimate of effect and likely to change the estimate.*Very low*---Very little confidence that the evidence reflect the true effect; the true effect is likely to be substantially different than the estimated effect. In addition, this rating may be used if there is no evidence or it is not possible to estimate an effect.

Results {#section8-2192568219829024}
=======

Study Selection {#section9-2192568219829024}
---------------

From 1039 potentially relevant citations identified, 1027 were excluded based on title and/or abstract review; twelve studies, all in the lumbar spine, were selected for full-text review ([Figure 1](#fig1-2192568219829024){ref-type="fig"}). Eight studies (from 10 publications) met the inclusion criteria, including 1 RCT (N = 24), 1 preliminary report from an ongoing phase I pilot RCT describing safety results (N = 24), 5 case series (7 publications) (N = 10-26), and 1 single-arm registry study (N = 33).^[@bibr29-2192568219829024],[@bibr30-2192568219829024],[@bibr43-2192568219829024][@bibr44-2192568219829024][@bibr45-2192568219829024][@bibr46-2192568219829024][@bibr47-2192568219829024][@bibr48-2192568219829024][@bibr49-2192568219829024]-[@bibr50-2192568219829024]^ Additionally, 10 ongoing clinical trials were identified (Appendix C). No additional studies were identified from hand searching bibliographies of included studies or identified systematic reviews.

![Flowchart showing results of literature search.](10.1177_2192568219829024-fig1){#fig1-2192568219829024}

No studies of cell-based therapy for cervical IVD repair were identified.

Both RCTs were considered at moderately high risk of bias. All case series were considered at high risk of bias. Methodological concerns included potential for selection bias (failure to describe patient selection methods and/or number of eligible patients and/or loss to follow-up) and lack of blinded outcomes assessment for patient-reported outcomes (Appendix B).

Key Question 1: Effectiveness of Cell Therapy {#section10-2192568219829024}
---------------------------------------------

Across included studies, populations were predominately male with mean ages of approximately 40 years who had failed previous conservative care. Two studies of allogenic cell sources^[@bibr44-2192568219829024],[@bibr46-2192568219829024]^ and 5 studies (7 publications) of autologous cell sources provided data on effectiveness.^[@bibr29-2192568219829024],[@bibr30-2192568219829024],[@bibr43-2192568219829024],[@bibr45-2192568219829024],[@bibr47-2192568219829024][@bibr48-2192568219829024]-[@bibr49-2192568219829024]^ [Table 1](#table1-2192568219829024){ref-type="table"} summarizes the pathologies, prior treatments, and levels treated. Details of cell preparation, sources and intervention specifics are found in the abstraction tables (Appendix D). Results and tables for primary outcomes (function, pain) are reported below; results for secondary outcomes are found in Appendix E.

###### 

Summary of Pathologies, Prior and Concurrent Treatment, and Spinal Levels Treated.

![](10.1177_2192568219829024-table1)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study (Design), ROB                                  Diagnosis                                                                                                         Previous Treatment and Concurrent Treatment                                                         N, Patients per Level, % (n/N)
  ---------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------
  *Allogenic*                                                                                                                                                                                                                                                                

  Noriega 2017 (RCT), *moderately high*\               Degenerative disc disease (radiculopathy, myelopathy NR)                                                          All unresponsive to conservative treatment for 6 months\                                            N = 24L1-2: 1,^a^ L2-3: 1L3-4: 3L4-5: 18L5-S1: 15
  MSCs vs sham                                                                                                                                                           Prior surgery: NR\                                                                                  
                                                                                                                                                                         Concurrent treatment: NR                                                                            

  Coric 2013 (case series), *high*\                    Single-level degenerative disc disease; low back pain (radiculopathy excluded)                                    All had failed ≥3 months conservative treatment\                                                    L3-4: 13.3% (2/15)L4-5: 6.7% (1/15)L5-S1: 80% (12/15)
  Chondrocytes                                                                                                                                                           Prior surgery: 0% (included patients who refused surgery)\                                          
                                                                                                                                                                         Concurrent treatment: NR                                                                            

  *Autologous MSCs*                                                                                                                                                                                                                                                          

  Centeno 2017 (case series), *high*\                  Degenerative disc disease, low back pain (chronicity NR) with radiculopathy                                       All had failed conservative treatment, interventional therapies (steroid injections) (length NR)\   N = 33L4-5: NRL5-S1: 66.7% (22/33)
  BMA                                                                                                                                                                    Prior surgery: 0% (included patients who refused surgery)\                                          
                                                                                                                                                                         Concurrent treatment: NR                                                                            

  Kumar 2017 (case series), *high*\                    Degenerative disc disease, chronic (\>3 months) axial discogenic low back pain (radiculopathy or myelopathy NR)   All had patients had failed conventional treatment (length NR)\                                     N = 10L4-5: 90% (9/10)L5-S1 + L4-5: 10% (1/10)
  Adipose-derived                                                                                                                                                        Prior surgery: 0%\                                                                                  
                                                                                                                                                                         Concurrent treatment: NR                                                                            

  Orozco 2011 (case series), *high*\                   Degenerative disc disease, chronic (not defined) low back pain                                                    All had failed conservative treatment (length of treatment NR)\                                     N = 10L4-5: 20% (2/10)L5-S1: 60% (6/10)L4-5 and L5-S1: 20% (2/10)
  BMA                                                                                                                                                                    Prior surgery: NR\                                                                                  
                                                                                                                                                                         Concurrent treatment: NR                                                                            

  Pettine 2015 \[2016, 2017\] (case series), *high*\   Degenerative disc disease (no further detail)                                                                     All had failed ≥3 months conservative treatment\                                                    N = 261-level (levels NR): 50% (13/26)2-level (levels NR): 50% (13/26)
  BMA                                                                                                                                                                    Prior surgery: NR\                                                                                  
                                                                                                                                                                         Concurrent treatment: NR                                                                            

  *Autologous hematopoietic stem cells*                                                                                                                                                                                                                                      

  Haufe 2006 (case series), *high*\                    degenerative disc disease (no further detail)                                                                     Prior surgery: NR\                                                                                  NR
  BMA                                                                                                                                                                    Prior treatment: NR\                                                                                
                                                                                                                                                                         Concurrent treatment: Hyperbaric oxygen therapy                                                     

  *Autologous chondrocytes*                                                                                                                                                                                                                                                  

  Tschugg 2016 (ongoing RCT), *Moderately high*\       Degenerative disc disease (no further detail)                                                                     All had failed conservative or interventional treatment (length NR)\                                N = 12 vs 8L3-L4: 8.3% vs 0%L4-L5: 25% vs 25%L5-S1: 66.6% vs 75%
  *Novocart Disc Basic vs Novocart Disc Plus*\                                                                                                                           Prior surgery: 0% (exclusion criteria); all received sequestrectomy as part of treatment\           
  Chondrocytes                                                                                                                                                           Concurrent treatment: NR                                                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: BMA, bone marrow aspirate; MSCs, mesenchymal stem cells; NR, not reported; RCT, randomized controlled trial; ROB, risk of bias.

^a^Number of patients per level not reported by treatment group for Noriega 2017. Patients may have had more than 1 level treated.

### Allogenic Cell Sources: Lumbar Spine {#section11-2192568219829024}

One small RCT (N = 24) at moderately high risk of bias comparing expanded allogenic MSC from healthy donors (intradiscal injection of 25 × 10^6^ cells per segment under local anesthesia) compared with sham injection of 2 mL of 1% mepivacaine into the paravertebral musculature was identified. Patients had chronic low back pain and degerative disc disease at 1 or 2 levels and had failed a minimum of 6 months conservative care.^[@bibr46-2192568219829024]^ L4-L5 and L5-S1 were the most common levels treated. No differences between allogenic MSC and sham treatment were seen for function based on Oswestry Disability Index (ODI), visual analogue scale (VAS)--pain, Short Form--36 (SF-36) Mental Component Score (MCS) or Physical Component Score (PCS) at any time frame, which may in part be due to small sample size ([Table 2](#table2-2192568219829024){ref-type="table"} and Appendix E). Similarly, there was no statistical difference between treatment groups in disc height decrease. Authors reported improved function and pain compared with baseline in the MSC group at 3, 6, and 12 months; again, no differences between treatment groups were noted.

###### 

Summary of Primary Outcomes (RCT and Case Series): Expanded Allogenic Cells for IVD Repair.

![](10.1177_2192568219829024-table2)

  ------------------------------------------------------------------------------------------------------------------------------------------------------
  Noriega 2017, RCT, Moderately High ROB\   Follow-up (Months)   Allogenic MSC (n = 12)\   Sham (n = 12) Mean ± SD\   MD (95% CI)^a^      *P* ^a^
  Outcome Measure                                                Mean ± SD\                Median (IQR)                                   
                                                                 Median (IQR)                                                             
  ----------------------------------------- -------------------- ------------------------- -------------------------- ------------------- --------------
  *Function*                                                                                                                              

  ODI (0%-100% \[worse\])                   0                    34 ± 23\                  24 ± 14\                   10 (−6.1, 26.1)     .2116
                                                                 26 (22-47)                22 (15-30)                                     

                                            3                    16 ± 20\                  25 ± 15\                   −9 (−23.9, 6.0)     .2255
                                                                 9 (6-16)                  24 (16-31)                                     

                                            6                    20 ± 24\                  30 ± 20\                   −10 (−28.7, 8.7)    .2795
                                                                 12 (7-19)                 28 (14-45)                                     

                                            12                   22 ± 24\                  34 ± 25\                   −12 (−32.7, 8.7)    .2431
                                                                 10 (8-24)                 29 (20-51)                                     

  *Pain*                                                                                                                                  

  VAS (0-100 \[worst\])                     0                    67 ± 26\                  62 ± 23\                   5 (−15.8, 25.8)     .6228
                                                                 70 (50-90)                71 (56-77)                                     

                                            3                    43 ± 30\                  46 ± 27\                   −3 (27.2, 21.2)     .7992
                                                                 40 (16-63)                50 (24-72)                                     

                                            6                    40 ± 29\                  51 ± 29\                   −11 (−35.5, 13.5)   .3629
                                                                 47 (12-60)                52 (26-79)                                     

                                            12                   47 ± 36\                  47 ± 28\                   0 (−27.3, 27.3)     1.0000
                                                                 47 (14-78)                54 (24-68)                                     

  Coric 2013, Single Level\                 Follow-up\           Allogenic Chondrocytes\   No Comparator              Effect Size         Across\
  Case Series, High ROB\                    (Months)             (n = 15), mean ± SD                                                      Time Periods
  Outcome Measure                                                                                                                         

  *Function*                                                     Δ vs baseline                                                            

  ODI (0%-100% \[worst\])                   0                    53.3 ± NR                 N/A                        N/A                 

                                            1                    27.6 ± NR                 N/A                        N/A                 \<.0001

                                            3                    27.1 ± NR                 N/A                        N/A                 

                                            6                    26.9 ± NR                 N/A                        N/A                 

                                            12                   20.3 ± NR                 N/A                        N/A                 

  *Function success* (ODI)                                       \% (n/N)                                                                 

  ≥30% Improvement                          12                   92.9% (13/15)             N/A                        N/A                 N/A

  *Pain*                                                         Δ vs baseline                                                            

  NPRS (0-100 \[worst\])                    0                    5.7 ± NR                  N/A                        N/A                 .0025

                                            1                    3.9 ± NR                  N/A                        N/A                 

                                            3                    3.5 ± NR                  N/A                        N/A                 

                                            6                    3.8 ± NR                  N/A                        N/A                 

                                            12                   3.1 ± NR                  N/A                        N/A                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CI, confidence interval; IQR, interquartile range; MD, mean difference between treatments; MSCs, mesenchymal stem cells; N/A, not applicable; NPRS, numeric pain rating scale; NR, not reported; ODI, Oswestry Disability Index; RCT, randomized controlled trial; ROB, risk of bias; SD, standard deviation; VAS, visual analogue scale.

^a^Effect sizes calculated unless otherwise indicated for comparison of treatment groups based on 2-sample *t* test for differences in means. *P* values for case series are as reported by study authors across time periods.

One small (N = 15) prospective case series (high risk of bias) using expanded, allogenic, cryopreserved juvenile chondrocytes (∼10^7^cells/mL in a fibrin carrier) from cadaveric articular surfaces for single level intervention was also identified.^[@bibr44-2192568219829024]^ Local anesthetic was used for all procedures. Allogenic chondrocyte implantation improved ODI and VAS scores ([Table 2](#table2-2192568219829024){ref-type="table"}) and SF-36 PCS through 12 months but not SF-36 MCS compared with baseline values (Appendix D1). Functional success and improvement in disc contour or height on magneric resonance imaging (definitions not provided) was achieved by the majority of patients (Appendix Tables D).

### Autologous Cell Sources: Lumbar Spine {#section12-2192568219829024}

All data was from 5 small case series (N = 10-33) considered to be at high risk of bias ([Table 1](#table1-2192568219829024){ref-type="table"}). Three series used MSC from bone marrow aspirate (BMA)^[@bibr29-2192568219829024],[@bibr43-2192568219829024],[@bibr47-2192568219829024][@bibr48-2192568219829024]-[@bibr49-2192568219829024]^; one combined MCS from adipose tissue with hyaluronic acid^[@bibr45-2192568219829024]^ and one used hematopoietic cells from BMA^[@bibr30-2192568219829024]^ (Appendix Tables D).

At 3, 6, and 12 months, 3 of the 5 series reported improved function based on mean ODI scores compared with baseline scores^[@bibr29-2192568219829024],[@bibr45-2192568219829024],[@bibr48-2192568219829024]^; however, one study reported no difference from baseline on the m-SANE (modified single assessment numeric evaluation) measure at any time frame.^[@bibr43-2192568219829024]^ The percent reduction in ODI compared with baseline was likely clinically significant (\>55%) at all time frames in 1 study^[@bibr48-2192568219829024]^ and a majority of patients achieved success (variably defined) in 2 other studies ([Table 3](#table3-2192568219829024){ref-type="table"}).^[@bibr43-2192568219829024],[@bibr45-2192568219829024]^ Variability around mean estimates is poorly reported or very large in most instances, making conclusions regarding estimate precision and stability difficult.

###### 

Summary of Functional Outcomes of Autologous Cells for Intervertebral Disc Repair Across Case Series.

![](10.1177_2192568219829024-table3)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome Measure\                        Mesenchymal Stem Cell Origin, Intervention   Author, Year    N    Mean ± SD              *P* (Δ vs Baseline)^a^
  Follow-up (Months)                                                                                                               
  --------------------------------------- -------------------------------------------- --------------- ---- ---------------------- ------------------------
  *Function* (means)                                                                                                               

  ODI (0-100%\[worst\])                                                                                                            

   Baseline                               BMA (Non-Exp.)                               Pettine, 2015   26   56.5 ± NR              N/A

                                          BMA (Non-Exp)                                Orozco, 2011    10   25.0 ± 13.0^b^         N/A

                                          Adipose MSCs (Exp.) + HA                     Kumar, 2017     10   42.8 ± 15.03           N/A

   3 months                               BMA (Non-Exp)                                Pettine, 2015   26   22.8 ± NR              ≤.0001

                                          BMA (Non-Exp)                                Orozco, 2011    10   13.0 ± 10.1^b^         \<.05

                                          Adipose MSCs (Exp.) + HA                     Kumar, 2017     10   31.7 ± 14.22           .01

   6 months                               BMA (Exp.)                                   Pettine, 2015   26   24.4 ± NR              ≤.0001

                                          BMA (Non-Exp)                                Orozco, 2011    10   9.4 ± 8.5^b^           \<.01

                                          Adipose MSCs (Exp.) + HA                     Kumar, 2017     10   21.3 ± 7.42            .002

   12 months                              BMA (Exp.)                                   Pettine, 2015   26   25.0 ± NR              ≤.0001

                                          BMA (Non-Exp)                                Orozco, 2011    10   7.4 ± 7.3^b^           \<.001

                                          Adipose MSCs (Exp.) + HA                     Kumar, 2017     10   16.8 ± 9.77            .002

  mSANE (−100% to 100%, 0% at baseline)                                                                                            

   3 months                               BMA (Exp.)                                   Centeno, 2017   30   47% ± NR               NS

   6 months                                                                                                 51% ± NR               NS

   12 months                                                                                                45% ± NR               NS

  *Function success*                                                                                                               

  \% reduction in ODI                                                                                       \% Δ from baseline     

  3 months                                BMA (Non-Exp.)                               Pettine, 2015   26   58.1%                  N/A

  6 months                                                                                                  55.5%                  N/A

  12 months                                                                                                 56.8%                  N/A

  m-SANE                                                                                                    \% of patients (n/N)   

  ≥50% improvement (mean 40.6 months)     BMA (Exp.)                                   Centeno, 2017   30   50.4% (n = NR)         N/A

  \>0% improvement (36 months)                                                                         30   90% (n = NR)           N/A

  ≥50% reduction in VAS and ODI                                                                                                    

   6 months                               Adipose MSCs (Exp.) + HA                     Kumar, 2017     10   70% (7/10)             N/A

   12 months                                                                                           10   60% (6/10)             N/A
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: BMA, bone marrow aspirate; Exp. = expanded cells; HA, hyaluronic acid; mSANE, modified Single Assessment Numeric Evaluation (−100% worsened to 100% improved, with pretreatment baseline at 0%); MSC, mesenchymal stem cells; N/A, not applicable; Non-Exp., nonexpanded cells; NR, not reported; NS, not statistically significant; ODI, Oswestry Disability Index (0%-100%, higher scores indicate greater disability); VAS, Visual Analogue Scale (0-100, higher scores indicate severity of pain).

^a^*P* values as reported by authors.

^b^ Where standard errors (SE) were reported, values were used to estimate standard deviation (SD): SD = SE × SQRT(n).

Pain reduction (VAS 0-100 scale) compared with baseline was also consistently seen following autologous cell therapy across most studies at most time frames ([Table 4](#table4-2192568219829024){ref-type="table"}). Exceptions were seen in one study of MCS from BMA, which reported no statistically significant change in VAS pain scores compared with baseline at 6 or 12 months^[@bibr43-2192568219829024]^ and in another study, which reported that pain reduction was not seen in any patient.^[@bibr30-2192568219829024]^ Pain reduction relative to baseline appeared to be clinically significant (58% to 64%) at 3, 6, and 12 months in 1 series.^[@bibr48-2192568219829024]^ Variability around mean estimates was poorly reported or very large in most instances, making conclusions regarding estimate precision and stability difficult.

###### 

Summary of Pain Outcomes of Autologous Cells for Intervertebral Disc Repair Across Common Time Frames Across Case Series.

![](10.1177_2192568219829024-table4)

  Outcome Measure                   Cell/Intervention          Author, Year    N    Mean ± SD                 *P*, Δ vs Baseline^a^
  --------------------------------- -------------------------- --------------- ---- ------------------------- -----------------------
  *VAS or NPRS* (0-100 \[worst\])                                                                             
  Baseline                          MSC (BMA, Non-Exp.)        Pettine, 2015   26   79.3 ± NR                 N/A
                                    MSC (BMA, Non-Exp.)        Orozco, 2011    10   68.9 ± 10.4^b^            N/A
                                    MSC (BMA, Exp.)            Centeno, 2017   25   52.0 ± NR                 N/A
                                    MSC (adipose, Exp.) + HA   Kumar, 2017     10   65 ± 12.7                 N/A
  3 months                          MSC (BMA, Non-Exp.)        Pettine, 2015   26   29.2 ± NR                 ≤.0001
                                    MSC (BMA, Non-Exp.)        Orozco, 2011    10   26.5 ± 17.7^b^            \<.001
                                    MSC (BMA, Exp.)            Centeno, 2017   25   Δ vs baseline 16.0 ± NR   \<.05
                                    MSC (adipose, Exp.) + HA   Kumar, 2017     10   43.0 ± 16.3               .02
  6 months                          MSC (BMA, Non-Exp.)        Pettine, 2015   26   26.3 ±NR                  ≤.0001
                                    MSC (BMA, Non-Exp.)        Orozco, 2011    10   21.6 ± 19.0†              \<.001
                                    MSC (BMA, Exp.)            Centeno, 2017   25   Δ vs baseline 14.0 ± NR   NS
                                    MSC (adipose, Exp.) + HA   Kumar, 2017     10   32.0 ± 14.0               .004
  12 months                         MSC (BMA, Non-Exp.)        Pettine, 2015   26   33.2 ± NR                 ≤.0001
                                    MSC (BMA, Non-Exp.)        Orozco, 2011    10   20.0 ± 20.6^b^            \<.001
                                    MSC (BMA, Exp.)            Centeno, 2017   25   Δ vs baseline 6.0 ± NR    NS
                                    MSC (adipose, Exp.) + HA   Kumar, 2017     10   29.0 ± 16.6               .002
                                    Hematopoietic (BMA^c^)     Haufe, 2006     10   Pain reduction in 0%^c^   
  \% Reduction in VAS score                                                         \% Δ from baseline        
  3 months                          MSC (BMA, Non-Exp.)        Pettine, 2015   26   64.6%                     N/A
  6 months                                                                          64.2%                     N/A
  12 months                                                                         58.0%                     N/A

Abbreviations: BMA, bone marrow aspirate; Exp., expanded cells; HA, hyaluronic acid; MSC, mesenchymal stem cells; N/A, not applicable; Non-Exp., nonexpanded cells; NPRS, numeric pain rating scale 0-10, 0 = no pain and 10 = worst possible pain; Converted to 0-100 scale for analysis; NR, not reported; NS, not statistically significant; VAS, visual analogue scale; 0-100, higher scores indicate severity of pain).

^a^*P* values as reported by authors.

^b^ Where standard errors (SE) were reported, values were used to estimate standard deviation (SD): SD = SE × SQRT(n).

^c^ Haufe (2006) does not specify whether cells were expanded or not; Only reported percentage with no pain reduction.

Success, defined as ≥50% reduction in VAS and ODI was achieved by 70% (7/10) patients at 6 months and maintained by 60% by 12 months in 1 small series (N = 10).^[@bibr45-2192568219829024]^

With regard to secondary outcomes, 1 series reported a significant difference in SF-36 PCS at 12 months, but not in the MCS in 1 series.^[@bibr29-2192568219829024]^ Disc height did not appear to change substantially from baseline based on 2 series^[@bibr29-2192568219829024],[@bibr45-2192568219829024]^ (Appendix Tables E).

Key Question 2: Safety {#section13-2192568219829024}
----------------------

### Allogenic Cell Sources {#section14-2192568219829024}

Evidence of safety across the 2 studies of allogenic cell sources was sparse. No major adverse events were identified in the RCT in either treatment group; authors reported that fewer allogenic MSC recipients required nonsteroidal anti-inflammatory drugs (NSAIDs; 25% vs 66.6%) versus sham and 8.3% of both groups received opioids.^[@bibr46-2192568219829024]^ Similarly, no treatment-related adverse events were observed in the case series of allogenic chondrocyte implantation; however, 20% (3/15) of participants had subsequent total disc arthroplasty by 12 months for persistent low back pain.^[@bibr44-2192568219829024]^ Neither study likely had sufficient power to detect rare adverse events ([Table 5](#table5-2192568219829024){ref-type="table"}).

###### 

Summary of Safety Outcomes.

![](10.1177_2192568219829024-table5)

  ------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome                                  Study (Design)                    Intervention vs Comparator (if Applicable), Effect Size (95% CI)^a^
  ---------------------------------------- --------------------------------- ---------------------------------------------------------------------
  *Allogenic*                                                                

  Serious adverse events                   Noriega, 2017 (RCT)               MSC (n = 12): 0% vs sham (n = 12): 0%

                                           Coric, 2013 (CS)                  Chondrocytes (N = 15): 0%

  Pain requiring opioids                   Noriega, 2017 (RCT)               MSC (n = 12): 8.3% (1/12) vs sham (n = 12): 8.3% (1/12)

  Minor pain (NSAID use)                                                     MSC (n = 12): 25% (1/12) vs sham (n = 12): 66.6%(8/12)

  Progression to surgery                   Coric, 2013 (CS)                  Chondrocytes (N = 15): 20% (3/15)

  *Autologous stem cells*                                                    

  Any complaint                            MSC: Centeno, 2017 (CS)           27% (9/33)

  Nonserious treatment-related AE                                            Pain-related^b^: 9.0% (3/33)\
                                                                             Other: 3% (1/33)

  Second injection                         MSC: Pettine, 2015 (CS)           6 months: 7.7% (2/26)

  Subsequent surgery                       MSC: Centeno, 2017 (CS)           6.0% (2/33)

                                           MSC: Pettine, 2015 (CS)           12 months: 7.7% (2/26)

                                                                             24 months: 19.2% (5/26)

                                                                             36 months: 23.1% (6/26)

                                           Hematopoietic: Haufe, 2006 (CS)   Fusion: 70% (7/10), TDR: 10%(1/10)

  *Autologous chondrocytes*                                                  

  Any AE (mild or moderate intensity)^c^   Tschugg, 2016 (RCT)               *Novocart Disc Basic vs Novocart Disc Plus*\
                                                                             50% (6/12) vs 25% (2/8); RR 2.0 (0.5, 7.5)

  Treatment-related AE^d^                                                    8.3% (1/12) vs 12/5% (1/8); RR 0.6 (0.06, 9.2)
  ------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AE, adverse event; CS, case series; HA, hyaluronic acid; MSC, mesenchymal stem cells; N/A, not applicable; NR, not reported; NSAID, nonsteroidal anti-inflammatory drug; RCT, randomized controlled trial; TDR, total disc replacement.

^a^Effects sizes included, when applicable, and calculated by Aggregate Analytics, Inc. (AAI).

^b^All events resolved; authors report an additional AE (large herniated nucleus pulposus occurring months following injection; unclear if procedure related or progression of degenerative process).

^c^Nasopharyngitis most common in the Novocart Disc (ND) plus group (n = 3); not associated with sequestrectomy or implantation; additional AEs not described.

^d^Events determined by investigator to be related to sequestrectomy and study treatment; including 1 patient with intervertebral disc protrusion (ND Plus group) and 1 patient with spinal pain after implant (ND Basic group).

### Autologous Cell Sources {#section15-2192568219829024}

Evidence for the safety of cell therapy across 5 small case series of autologous cells sources was sparse and poorly reported. The need for subsequent surgery was reported across 3 series was high (6% to 80%) ([Table 5](#table5-2192568219829024){ref-type="table"}). The patient populations consisted of those who had already failed conservative care. No serious adverse events (treatment related or otherwise) were observed in the 4 series reporting on such events; however, studies may have been underpowered to detect such events. Two series reported that no nonserious treatment-related adverse events were observed^[@bibr29-2192568219829024],[@bibr45-2192568219829024]^ and 1 series reporting pain-related events that resolved.^[@bibr43-2192568219829024]^

One small, moderately high risk of bias phase I pilot RCT (N = 24)^[@bibr50-2192568219829024]^ comparing autologous disc chondrocyte transplantation with Novocart Disc Plus (ND Plus) versus Novocart Disc Basic (ND Basic) reported preliminary safety data through 6 weeks only, of patients with symptomatic low back pain who failed adequate conservative or interventional treatment. Sequestrectomy of the affected disc was performed and the extracted tissues were transferred for manufacturing of ND Plus. The pilot was considered of poor quality due to inadequate concealment of treatment allocation, differential loss to follow-up, and differences in patient baseline characteristics (the ND Plus group had higher proportion of patients that were male, and proportions who reported tobacco use and full-time work; fewer ND Plus patients had adjacent degenerative disc disease and reported less analgesic medication use, particularly NSAIDS. Adverse events were more common in the ND Plus group (50%, 6/12) compared with the ND Basic group (25%, 2/8) and only 1 treatment event was considered serious (IVD protrusion) and the patient underwent further surgery. Authors reported nasopharyngitis as the most common event. Firm conclusions regarding the relative safety of the two cell preparations were not possible given the study limitations.

Key Question 3: Modification of Treatment Effect {#section16-2192568219829024}
------------------------------------------------

### Allogenic Cell Sources {#section17-2192568219829024}

Included studies were not designed to evaluate modification of treatment by demographic or other factors and none reported subgroup analyses on factors of interest (eg, number of treated levels).

### Autologous Cell Sources {#section18-2192568219829024}

Included studies were not designed to evaluate modification of treatment by demographic or other factors and with one exception did not provide information on such factors. One small (N = 26) case series^[@bibr48-2192568219829024]^ provided limited subgroup data for patients who had 1- versus 2-level injection, those aged ≤40 years old versus \>40 years old and for MSC concentrations of \<2000 CFU-F (colony-forming unit fibroblasts) with \>2000 CFU-F ([Table 6](#table6-2192568219829024){ref-type="table"}). Statistical analyses were only reported for the comparison of cell concentrations. Authors reported that mean ODI and VAS scores were significantly improved for patients receiving \>2000 CFU-F compared with those receiving \<2000 CFU-F. As these reports do not compare MSC to an alternative treatment, conclusions regarding modification of treatment effect (heterogeneity of treatment effect) were not possible. Conclusions regarding comparisons within the other subgroups were not possible as data provided were inadequate for analysis.

###### 

Key Question 3: Subanalyses (Across All Patients From Authors' Original Population; Pettine, 2015).

![](10.1177_2192568219829024-table6)

  ------------------------------------------------------------
  Outcome\     Group A,\          Group B,\          *P* ^a^
  Follow-up    Mean ± SD          Mean ± SD          
  ------------ ------------------ ------------------ ---------
               Age ≤40 Years\     Age \>40 Years\    
               (n = 14)           (n = 12)           

  *Mean ODI*                                         

  Baseline     57.1 ± NR          55.8±NR            N/A

  3 months     18.2 ± NR          27.8±NR            NR

  6 months     20.6 ± NR          28.5±NR            NR

  12 months    25.1 ± NR          24.8±NR            NR

  *Mean VAS*                                         

  Baseline     83.4 ± NR          74.8±NR            N/A

  3 months     24.6 ± NR          34.2±NR            NR

  6 months     23.5 ± NR          29.2±NR            NR

  12 months    32.3 ± NR          34.5±NR            NR

               \<2000 CFU-F\      \>2000 CFU-F\      
               (n = 9)            (n = 11)           

  *Mean ODI*                                         

  Baseline     54.2 ± NR          59.3 ± NR          N/A

  3 months     33.7 ± NR          14.8 ± NR          \<.005

  6 months     36.3 ± NR          13.5 ± NR          \<.005

  12 months    26.3 ± NR          17.6 ± NR          NR

  *Mean VAS*                                         

  Baseline     80.4 ± NR          82.0 ± NR          N/A

  3 months     46.4 ± NR          17.5 ± NR          \<.005

  6 months     36.7 ± NR          10.8 ± NR          \<.01

  12 months    34.5 ± NR          25.5 ± NR          \<.0001

               1-Level (n = 13)   2-Level (n = 13)   

  *Mean ODI*                                         

  Baseline     56.5 ± NR          55.5 ± NR          N/A

  3 months     18.4 ± NR          27.4 ± NR          NR

  6 months     19.8 ± NR          29.3 ± NR          NR

  12 months    26.2 ± NR          22.7 ± NR          NR

  *Mean VAS*                                         

  Baseline     78.5 ± NR          79.4 ± NR          N/A

  3 months     23.8 ± NR          34.8 ± NR          NR

  6 months     20.2 ± NR          32.7 ± NR          NR

  12 months    31.4 ± NR          33.0 ± NR          NR
  ------------------------------------------------------------

Abbreviations: CFU-F, colony-forming unit fibroblast; N/A, not applicable; NR, not reported; ODI, Oswestry Disability Index; VAS, visual analogue scale.

^a^Reported by authors for comparison between subgroups as available. Data is insufficient to calculate differences between subgroups.

Key Question 4: Economic Studies {#section19-2192568219829024}
--------------------------------

No full economic studies were identified for either lumbar or cervical IVD.

Evidence Summary, Overall Quality (Strength) of Evidence {#section20-2192568219829024}
--------------------------------------------------------

No evidence on use of cell therapy for cervical IVD repair was identified. Studies of cell therapy for lumbar IVD repair primarily consisted of small case series. The quality of evidence was very low with regard to the benefits and safety of stem cell therapy for lumbar IVD repair in patients who have failed conservative care primarily due to substantial risk of bias and lack of precision, ([Tables 7](#table7-2192568219829024){ref-type="table"} and [8](#table8-2192568219829024){ref-type="table"}).

###### 

Evidence Summary: Overall Quality (Strength) of Evidence for Effectiveness and Safety of Allogenic Cell Therapy for Lumbar Intervertebral Disc Repair.^a^

![](10.1177_2192568219829024-table7)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome                        Studies\                  Serious Risk of Bias   Serious Inconsistency   Serious Indirectness   Serious Imprecision   Overall Quality of Evidence   Findings
                                 N\                                                                                                                                                  
                                 (Treatments)                                                                                                                                        
  ------------------------------ ------------------------- ---------------------- ----------------------- ---------------------- --------------------- ----------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Function (mean ODI, success)   1 RCT (N = 24)\           RCT\                   Unknown^§^              No                     RCT:\                 Very low (RCT)\               **RCT:** No difference in function between allogenic MSC and sham at 3, 6, or 12 months; findings may in part be due to small sample size**CS:** Allogenic chondrocyte implantation improved function compared with baseline status at all times to 12 months; 92% of participants achieved ≥30% improvement in ODI compared with baseline. Firm conclusions regarding effectiveness are not possible without comparison to another treatment however.
                                 (MSC vs sham)\            Yes (−1)\*\                                                           Yes (−1)^‡^\          Very low (CS)                 
                                 Noriega 2017\             CS\                                                                   CS\                                                 
                                 1 case series (N = 15)\   Yes (−1)^†^                                                           Yes (−1)^‡^                                         
                                 (chondrocytes)\                                                                                                                                     
                                 Coric 2013                                                                                                                                          

  Mean pain (VAS)                1 RCT (N = 24)\           RCT\                   Unknown^§^              No                     RCT: Yes (−1)^‡^\     Very low (RCT)\               **RCT:** No difference in mean pain between allogenic MSC and sham at 3, 6, or 12 months; findings may in part be due to small sample size**CS:** Allogenic chondrocyte implantation improved mean pain compared with baseline status at all times to 12 months; however, firm conclusions regarding effectiveness is not possible without comparison to another treatment.
                                 (MSC vs sham)\            Yes (−1)\*\                                                           CS: Yes (−1)^‡^       Very low\                     
                                 Noriega 2017\             CS\                                                                                         (CS)                          
                                 1 Case series (N = 15)\   Yes (−1)^†^                                                                                                               
                                 (chondrocytes)\                                                                                                                                     
                                 Coric 2013                                                                                                                                          

  Harms, adverse events          1 RCT (N = 24)\           RCT\                   Unknown^§^              No                     RCT: Yes (−2)^‡^\     Very low (RCT)\               **RCT:** No major adverse events identified; fewer allogenic MSC recipients required NSAIDs (25% vs 66.6%) versus sham and 8.3% of both groups received opioids.**CS:** No major adverse events identified; 20% (3/15) of participants had disc arthroplasty by 12 months for persistent LBPNeither study likely had sufficient statistical power to detect rare adverse events.
                                 (MSC vs sham)\            Yes (−1)\*\                                                           CS: Yes (−2)^‡^       Very low\                     
                                 Noriega 2017\             CS\                                                                                         (CS)                          
                                 1 case series (N = 15)\   Yes (−1)^†^                                                                                                               
                                 (chondrocytes)\                                                                                                                                     
                                 Coric 2013                                                                                                                                          
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CS, case series; LBP, low back pain; MSC, mesenchymal stem cell; NSAID, nonsteroidal anti-inflammatory drugs; ODI, Oswestry Disability Index; RCT, randomized controlled trial; VAS, visual analogue scale.

^a^Reasons for downgrading quality of evidence (general): \*Serious risk of bias: the majority of studies did not meet one or more criteria of a good-quality RCT (see Appendix for details). ^†^Serious risk of bias: the majority of studies did not meet two or more criteria of a good quality cohort or are case series (see Appendix for details). ^‡^Small sample size/insufficient power and/or significant variation in estimates (eg, wide confidence intervals, large standard deviations, etc). Imprecise effect estimate for an outcome: small sample size and/or confidence interval includes both negligible effect and appreciable benefit or harm with the intervention; If sample size is likely too small to detect rare outcomes, evidence may be downgraded twice. If the estimate is statistically significant, it is imprecise if the CI ranges from "mild" to "substantial." If the estimate is not statistically significant, it is imprecise if the CI crosses the threshold for "mild/small" effects. Wide (or unknown) confidence interval and/or small sample size may result in downgrade. ^§^Unknown consistency; single study or different measures used across studies. Inconsistency: differing estimates of effects across trials. If point estimates across trials are in the same direction, do not vary substantially or heterogeneity can be explained, results may not be downgraded for inconsistency. \*\*Indirect, intermediate, or surrogate outcomes may be downgraded. ^††^Reporting bias suspected: limited assessment or limited reporting of specific outcomes.

###### 

Evidence Summary: Overall Quality (Strength) of Evidence for Effectiveness and Safety of Autologous Cell Therapy for Lumbar Intervertebral Disc Repair.^a^

![](10.1177_2192568219829024-table8)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome                                        Studies\                                                               Serious Risk of Bias   Serious Inconsistency   Serious Indirectness   Serious Imprecision   Overall Quality of Evidence   Findings
                                                 N\                                                                                                                                                                                               
                                                 (Treatments)                                                                                                                                                                                     
  ---------------------------------------------- ---------------------------------------------------------------------- ---------------------- ----------------------- ---------------------- --------------------- ----------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Function (mean ODI, mean m-SANE and success)   4 Case series\                                                         Yes (−1)^†^            No                      No                     Yes (−1)^‡^           Very low                      Three series reported improved function based on mean ODI scores compared with baseline scores; clinically important reduction (\>55%) was reported in one, In one series, m-SANE mean scores were not significantly improved relative to baseline; however, the majority of patients (50.4%) achieved ≥50% improvement m-SANE scores by last follow-up.Firm conclusions regarding effectiveness are not possible without comparison with another treatment.
                                                 (N = 76)\                                                                                                                                                                                        
                                                 Pettine, 2015; Orozco, 2011; Kumar, 2017; Centeno, 2017                                                                                                                                          

  Pain                                           5 Case series\                                                         Yes (−1)^†^            Yes (−1)^§^             No                     Yes (−1)^‡^           Very low                      Pain reduction compared with baseline was seen in 3 of the 5 series at most time frames; reduction was clinically significant (58% to 64%) at all times to 12 months in one series.Firm conclusions regarding effectiveness are not possible without comparison to another treatment.
                                                 (N = 86)\                                                                                                                                                                                        
                                                 Pettine, 2015; Orozco, 2011; Kumar, 2017; Centeno, 2017; Haufe, 2006                                                                                                                             

  Success: ≥50% reduction in VAS and ODI         1 Case series (N = 10)\                                                Yes (−1)^†^            Unknown^§^              No                     Yes (−1)^‡^           Very low                      Success was achieved by 70% (7/10) patients at 6 months and maintained by 60% by 12 months.Firm conclusions regarding effectiveness are not possible without comparison to another treatment.
                                                 Kumar, 2017                                                                                                                                                                                      

  Harms, adverse events                          4 Case series\                                                         Yes (−1)^†^            Unknown^§^              No                     Yes (−1)^‡^           Very low                      Evidence for safety is sparse; studies may have been underpowered to detect adverse events.No serious adverse events (treatment related or otherwise) were observed.High rates (6% to 80%)of subsequent surgery were reported in 3 series; all patients had failed conservative care.
                                                 (N = 76)\                                                                                                                                                                                        
                                                 Pettine, 2015; Orozco, 2011; Kumar, 2017; Centeno, 2017                                                                                                                                          
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CS, case series; m-SANE, modified single assessment numeric evaluation; MSC, mesenchymal stem cell; ODI, Oswestry Disability Index; VAS, visual analogue scale.

^a^ Reasons for downgrading quality of evidence (general): \*Serious risk of bias: the majority of studies did not meet one or more criteria of a good-quality RCT (see Appendix for details). ^†^Serious risk of bias: the majority of studies did not meet two or more criteria of a good quality cohort or are case series (see Appendix for details). ^‡^Small sample size/insufficient power and/or significant variation in estimates (eg, wide confidence intervals, large standard deviations, etc). Imprecise effect estimate for an outcome: small sample size and/or confidence interval includes both negligible effect and appreciable benefit or harm with the intervention. If sample size is likely too small to detect rare outcomes, evidence may be downgraded twice. If the estimate is statistically significant, it is imprecise if the CI ranges from "mild" to "substantial." If the estimate is not statistically significant, it is imprecise if the CI crosses the threshold for "mild/small" effects. Wide (or unknown) confidence interval and/or small sample size may result in downgrade. ^§^Unknown consistency; single study or different measures used across studies. Inconsistency: differing estimates of effects across trials. If point estimates across trials are in the same direction, do not vary substantially or heterogeneity can be explained, results may not be downgraded for inconsistency. \*\*Indirect, intermediate, or surrogate outcomes may be downgraded. ^††^Reporting bias suspected: limited assessment or limited reporting of specific outcomes.

Discussion {#section21-2192568219829024}
==========

The overall strength of evidence for efficacy and safety of cell therapy for lumbar IVD repair was very low. No studies focusing on cervical spine were identified. Cellular therapies for IVD regeneration propose to restore nucleus pulposus and maintain normal extracellular matrix production by injecting allogenic or autologous disc cells, chondrocytes, or undifferentiated stem cells. Immunomodulatory effects of MSCs on NP cells in response to inflammatory cytokines could potentially prevent the aggravation of inflammatory cascade, thereby obviating ingrowth of pain-inducing vasculature and nerve fibers.^[@bibr18-2192568219829024]^ In our analysis, one study showed clinically significant (\>55%) reduction in ODI^[@bibr47-2192568219829024][@bibr48-2192568219829024]-[@bibr49-2192568219829024]^ while in another study clinical treatment success was achieved in 70% of the patients.^[@bibr45-2192568219829024]^ Three studies reported improved VAS scores using autologous cell based intervention^[@bibr29-2192568219829024],[@bibr45-2192568219829024],[@bibr47-2192568219829024][@bibr48-2192568219829024]-[@bibr49-2192568219829024]^ whereas 2 studies using BMA or hematopoietic stem cells BMA, showed no improvement with autologous cell-based intervention.^[@bibr30-2192568219829024],[@bibr43-2192568219829024]^ Need for subsequent surgery after cell therapy could not be clearly determined due to the inconsistency and disparity across the studies. Analysis across few studies showed need for subsequent surgery ranging from 6% to 80%.^[@bibr30-2192568219829024],[@bibr43-2192568219829024],[@bibr44-2192568219829024],[@bibr47-2192568219829024][@bibr48-2192568219829024]-[@bibr49-2192568219829024]^

Among several factors defining efficacy and feasibility, the disc level and severity of spine pathology are major factors dictating the success of cell transplantation. Moderate disc degeneration has been considered as an optimal target for stem cell therapy.^[@bibr51-2192568219829024]^ Two studies^[@bibr44-2192568219829024],[@bibr45-2192568219829024]^ indicated clinical improvement with autologous adipose tissue--derived MSCs (AT-MSCs) and allogenic juvenile chondrocytes in Pfirmann grade III-IV discs, respectively. In another study, patients with Pfirmann grade IV-VII showed significant improvement in VAS scores as well.^[@bibr47-2192568219829024][@bibr48-2192568219829024]-[@bibr49-2192568219829024]^ Noriega et al^[@bibr46-2192568219829024]^ included patients with Pfirmann grade II and reported improvement with allogenic MSCs compared with the baseline measurement. Results from these studies support the notion that cell therapy has a potential to reverse degenerative cascades.

The use of allogenic MSCs remains a significant issue due to the potential of immune rejection. Additionally, the injected dose and cell viability are key variables. Coric et al^[@bibr44-2192568219829024]^ transplanted a wide range of juvenile derived chondrocytes (between 6.75 and 13.5 × 10^6^ cells/mL) and demonstrated promising results for the use of juvenile-derived chondrocytes. Considering that disc is acellular and aging reduces cell density, cell doses exceeding the normal range might not prove beneficial in obviating degeneration. Thus, a low cell dose might be beneficial considering poor nutrient supply and hypoxic environment. Higher numbers of cells exceeding the capacity of NP might eventually lead to accumulation of dead cells, thereby invoking inflammatory response.^[@bibr1-2192568219829024]^ Cell leakage is another potential adverse event of cell-based therapies. Bertram et al^[@bibr52-2192568219829024]^ demonstrated up to 50% reduction in cell leakage with fibrin glue co-administration. In our systematic review, 1 study combined AT-MSCs with hyaluronic acid derivative and showed its safety and tolerability.^[@bibr45-2192568219829024]^

Previously, Meisel et al^[@bibr53-2192568219829024],[@bibr54-2192568219829024]^ have shown greater pain reduction at the 2-year follow-up in patients treated with autologous cultured disc--derived chondrocytes compared with patients who received surgical intervention. However, the autologous, noncultured cells reduce the risks of rejection, disease transmission, sample mismatch compared with culture expanded autologous or allogenic cells. Moreover, culture conditions (eg, media reagents, oxygen concentration, pH, etc) might affect cell characteristics and efficacy. Pettine et al^[@bibr48-2192568219829024]^ showed significant clinical improvement with uncultured BMA MSCs. Kumar et al^[@bibr45-2192568219829024]^ used AT-MSCs, where cell extraction is less invasive compared with bone marrow. AT-MSCs have additional advantage as they express higher levels of TβRIII, thus have a higher chondrogenic potential.^[@bibr55-2192568219829024]^

Hernigou et al^[@bibr56-2192568219829024]^ reported no increased incidence of cancers with autologous BMC injections for up to 22 years posttreatment. Concerns remain, however, about potential systemic infections, tumor growth, and other adverse events with the use of cell therapies. The studies in this systematic review did not report any major adverse events, however it is highly likely that studies included in the review were not equipped sufficiently to identify rare events. To address the host acceptability for the transplanted cells, monitoring of pro-inflammatory response indicators such as C-reactive protein might be helpful in identifying complications like an autoimmune response. Tschugg et al^[@bibr50-2192568219829024]^ applied this approach to identify incidence of immunological adverse events after intradiscal injection in the ND Plus and ND Basic cohorts. The study showed no indication of clinically significant immunological consequences.^[@bibr50-2192568219829024]^

Evidence for the efficacy and safety of cell therapy for lumbar IVD repair (allogenic or autologous) was very low, primarily due to the high risk of bias and lack of RCTs. While most case series suggested improved function and pain following cell therapies, the results need to be considered within the context of these limitations. It is not clear to what extent benefits would be seen if directly compared with other minimally invasive or surgical treatments. The only RCT in this systematic review found no difference between allogenic and sham groups in pain or function up to 1 year but may have been underpowered to detect differences between groups. The identified studies lacked subgroup analyses to determine association between patient characteristics or comorbidities with cell therapy success rate.

Furthermore, in our analysis no publications on cervical IVD repair met the inclusion criteria. No conclusion about cost-effectiveness of cell therapy over surgical treatment could be derived due to the lack of comparative economic studies. Low back and neck pain are one of the main drivers of years lived with disability worldwide. In the United States alone, the annual cost for the treatment of chronic low back pain exceeds \$100 billion.^[@bibr57-2192568219829024]^

Conclusions regarding safety are limited. While no serious adverse events were reported, sample sizes were likely inadequate to detect events, particularly those considered to be rare. Despite favorable risk-benefit ratio indicated by clinical studies, clinical evidence for cell based therapies needs to be established.

Conclusions {#section22-2192568219829024}
===========

The quality of evidence for the use of either allogenic or autologous cells for IVD repair was very low. Studies lacked tools to assess treatment heterogeneity depending on patient characteristics, co-intervention or other factors. While no serious adverse events were reported, sample sizes were likely inadequate to detect adverse events, particularly those considered to be rare. To evaluate the efficacy and safety of cell therapies for IVD repair, high-quality comparative studies are needed.
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